Advertisements

Гвайазулен

Quick links to important sections

Гвайазулен

Selected form

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Гвайазулен

Quick Facts

Property Description
Active Ingredient (INN) Гвайазулен (Guaiazulene)
Forms Available Tablets, Gels, Solutions
Pharmacological Class Anti-inflammatory and Anti-allergic Agent
Origin Sesquiterpene derivative from Chamomile oil (Natural/Synthetic)
Primary Benefit Helps reduce swelling and manage general irritation

What Type of Medicine is Гвайазулен and What is its Origin?

Гвайазулен (Guaiazulene) is an active pharmaceutical ingredient, chemically defined as 1,4-dimethyl-7-(2-propyl)azulene, that is clinically recognized for its properties as an anti-inflammatory and anti-allergic agent. The substance is a bicyclic sesquiterpene hydrocarbon, placing it within the azulene chemical family.

The compound belongs to a distinct pharmacological class that confers an antiphlogistic effect, helping to reduce local inflammation. Гвайазулен has a dual origin; it is structurally related to the blue compounds found in essential oils like chamomile oil, though its medical preparations are typically either highly purified natural derivatives or synthetic equivalents to ensure consistency. It acts as an antiallergic agent and a cell membrane stabilizer, helping to calm the body's response at a cellular level.

What are the Forms and Primary Benefits of Guaiazulene?

Guaiazulene is supplied in several drug forms suitable for either oral or topical administration, including coated tablets and specialized gels or solutions. The general purpose of Гвайазулен is to provide relief by offering a membrane stabilizer effect. This core action ensures the primary benefit is the reduction of discomfort and swelling associated with various inflammatory conditions.

As a differentiating factor, Guaiazulene is frequently utilized in combination products, often alongside agents targeting functional digestive disturbances, distinguishing its approach from typical single-ingredient anti-inflammatories.

Advertisements

What side effects are possible with Гвайазулен?

Possible side effects and safety information

The safety profile for Guaiazulene, as documented in regulatory sources, is primarily defined by the potential for allergic reactions, which are officially classified as rare events. The side effects listed in official prescribing information are based on system-organ class groupings utilized in medical regulatory documentation.


Officially Documented Adverse Reactions

The adverse reactions associated with the use of Guaiazulene are mainly related to skin and immune system responses. The most critical adverse events reported in product summaries are categorized by official regulatory terminology as exceptionally reported.

Classification Adverse Reaction System-Organ Class
Exceptionally Reported Hypersensitivity reactions Immune system disorders
Exceptionally Reported Rash, Pruritus (Itching) Skin and subcutaneous tissue disorders

Serious adverse reactions are primarily the potential for a severe expression of these hypersensitivity events, such as anaphylaxis, which, while rare, involves significant systemic impact. Additionally, skin reactions like contact dermatitis and increased photosensitivity (abnormal reaction to sunlight) are noted in safety summaries, particularly with topical use.


Population and Use Restrictions

Contraindications: The medicine is explicitly contraindicated for use in individuals with a known hypersensitivity to Guaiazulene or to any other component contained in the specific formulation. This is the primary safety restriction documented in regulatory labels.

Population Considerations: Official regulatory documents note a lack of specific clinical data concerning the use of Guaiazulene during pregnancy and lactation, which necessitates caution in these populations. The regulatory focus remains on the documented risk of allergic response and the formal absence of data in specific high-risk groups.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Гвайазулен (Guaiazulene) overdose is primarily defined by the explicit omission of specific clinical details in authoritative governmental labels, such as the European Summary of Product Characteristics (SmPC).

Overdose Scope

The formal regulatory documentation does not formally list specific expected signs, symptoms, or clinical manifestations related to Гвайазулен overdose. Consequently, no specific physiological systems are documented in this section as being distinctly affected.

  • No explicit, pre-defined emergency-response instructions or triggers for when medical help must be sought are formally documented, due to the lack of specific listed clinical manifestations.
  • No specific population-related overdose risks are formally documented.

Overdose Classifications

Severity classification: No formal severity classification (e.g., life-threatening) is defined in the official regulatory documents for Гвайазулен overdose. Overdose-context constraints: The main constraint is the explicit absence of specific clinical data in the regulatory overdose section.

Official Overdose Statements

  • The official regulatory documentation explicitly states the lack of available clinical data for overdose, often classifying the section as "Not applicable."
  • No specific antidote, procedural management steps, or severe outcomes are formally documented.
  • The only specific finding noted in the wider regulatory text is the appearance of traces of Guaiazulene in plasma following administration of doses well above the therapeutic posology.

Connection to the overall overdose profile

The drug’s official overdose profile is defined by the formal lack of specific clinical documentation in governmental labels. This informs the reader that official sources do not specify clinical manifestations or mandated emergency actions based on defined symptoms. The profile, therefore, describes the regulatory status of the drug's overdose information rather than an expected clinical presentation.

Advertisements

Therapeutic Uses of Гвайазулен

What Гвайазулен Treats: Main Uses and Benefits

Гвайазулен (Guaiazulene) is considered relevant for its supportive role in symptomatic relief across key therapeutic domains: used for addressing symptoms related to inflammatory or irritative states in the digestive system and addressing reactive skin conditions. Its anti-inflammatory and protective properties are relevant to its therapeutic application. It is commonly applied in clinical settings that involve acute or unstable symptom patterns where additional management of discomfort is required.

Easing Discomfort in Functional Digestive Disorders

This domain addresses symptom clusters that may become intense or disruptive within the upper gastrointestinal tract. Гвайазулен is applied in addressing conditions presenting with systemic or localized discomfort, including Gastritis, Functional Dyspepsia, and symptomatic episodes of Peptic Ulcers. It is used in situations involving recurrent or episodic manifestations, focusing on providing a soothing, protective benefit that may assist with easing symptoms related to physical discomfort.

Calming Inflammatory Skin Reactions

The medicine is applicable in conditions characterized by periods of heightened symptoms involving inflammatory or irritative processes in the skin. It is used to help manage the distressing manifestations of Dermatitis, Eczema, and general rashes. It helps address symptom clusters that may become intense or disruptive, including local swelling, redness, and itching. This application contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

“It is commonly used to help manage symptoms associated with both functional digestive issues and localized inflammatory skin problems, supporting general well-being during symptomatic phases.”


Quick Fact: Symptomatic Support for Inflammatory States
Primary Focus: Symptomatic relief in contexts where localized inflammation and irritation create noticeable physiological strain in the gastrointestinal tract and on the skin.
Advertisements

Eligibility and Restrictions for Use

The official regulatory profile for the use of Гвайазулен is defined primarily by two absolute non-eligibility criteria. The medicine is formally contraindicated in patients who have a known hypersensitivity (allergy) to Гвайазулен, Dimeticone, or any of the product’s excipients. An additional absolute constraint exists for individuals diagnosed with hereditary fructose intolerance, which prohibits use due to the presence of sorbitol in the formulation.

For all other populations, use is generally permitted. The regulatory label does not impose formal restrictions on the basis of age, and there are no documented contraindications concerning hepatic or renal impairment. Regarding reproductive status, the medicine is officially permitted for use during both pregnancy and lactation under normal conditions. A conditional restriction applies to patients with a general intolerance to some sugars, who are instructed to consult a healthcare provider before use. The eligibility status is based on the authoritative regulatory documentation from national medicines agencies.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Гвайазулен (Guaiazulene) is primarily defined by the absence of formally documented systemic interactions in major government prescribing information. This position aligns with the product's structure and the limited systemic absorption associated with its most common formulations.

Official Interaction Statements

Regulatory documentation reviewed by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) does not contain explicit warnings or requirements regarding co-administration.

Interaction Type Regulatory Status (Official Documentation)
Contraindications / Prohibitions No formal drug-drug or drug-substance combinations are explicitly documented as contraindicated.
Pharmacokinetic Basis No specific metabolic (e.g., Cytochrome P450 enzyme) or transporter-mediated interactions are officially cited as the basis for a clinical restriction.
Timing Requirements No mandatory timing or dose separation requirements are documented for co-administration with other medicines.
Food, Alcohol, Supplements No formal interaction restrictions are stated for use with food, alcohol, or herbal supplements.

Connection to the Overall Interaction Profile

The absence of specific, documented interactions means there are no mandated regulatory requirements for co-administration restrictions, specific timing rules, or interaction-related dose adjustments. The regulatory structure is silent on substances that modify the drug's systemic exposure, confirming that its primary profile does not include clinically significant drug-drug interaction risks based on current government labeling.

Advertisements

Mechanism of Action

Direct Modulation of Inflammatory Enzymes and Signals

Guaiazulene engages key molecular pathways by inhibiting the Cyclooxygenase-2 (COX-2) enzyme and suppressing the synthesis of pro-inflammatory cytokines. This action leads to a biochemical reduction in prostaglandin synthesis, which are key mediators that increase vascular permeability and local temperature, thus modulating a key process within the inflammatory cascade.


Stabilization of Cell Membranes and Mediator Release

The molecule interacts directly with the membranes of immune cells, such as mast cells, conferring stability against destabilizing stimuli. By restricting the rapid release of pre-formed mediators like histamine, this mechanism maintains cell integrity against stimuli that induce degranulation, thereby reducing the subsequent increase in vascular permeability.


Neutralization of Free Radicals (Antioxidant Action)

Guaiazulene functions as an antioxidant, interacting with Reactive Oxygen Species (ROS) (free radicals) that are generated during the inflammatory process. This intrinsic property neutralizes ROS, mitigating oxidative stress and limiting cellular lipid peroxidation.

Advertisements

Dosage and Administration Information

How to Use Гвайазулен: Official Administration Guidelines

This section outlines the standardized, formal instructions for administering Гвайазулен (Guaiazulene).

Approved Administration Routes and Dosing

Гвайазулен is approved for use via two primary routes: oral for systemic or gastrointestinal application and topical for localized use on the skin or mucous membranes. This ensures the correct dosage form is matched to the required application site.

Administration Route Typical Dosing Unit (Oral) Frequency Course Duration
Oral (e.g., Gel/Tablet) 4 mg per sachet/unit Up to three times daily (TID) Usually limited to 28 days
Topical (e.g., Gel/Cream) Varies by formulation As directed by application area Determined by professional guidance

Specific Instructions for Oral Use

For oral formulations, the proper administration technique and timing are specified to ensure correct use.

  • Timing: The oral dose (e.g., 4 mg sachet) must be taken before meals or when the pain occurs.
  • Preparation: The full content of the oral gel sachet is intended to be swallowed directly, followed by a few sips of water to ensure complete ingestion. It is not intended for prior mixing or dilution.

Use in Specific Populations

Official prescribing information for Гвайазулен generally does not contain explicit, quantified dose adjustment tables for common patient groups such as the older adults or those with renal or hepatic impairment. Any necessary modifications in these populations must be determined by a healthcare provider, in line with established clinical principles.

These instructions define the standardized, procedural use of the medicine.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase III Clinical Trials

Research focused on individuals diagnosed with a specific inflammatory condition, primarily those with moderate to severe cases.

Study Design Elements

Research evaluated the study drug’s activity in inflammation pathways. Research explored the relationship between the study drug and Substance P levels. Studies have also explored the influence on T-cell activation markers.

Primary Endpoints Investigated

Studies reported changes in patient-reported pain scores. The primary outcome measure was the Patient Global Assessment score, which was tracked over a six-month period. Changes in swelling were noted over 12 weeks.

  • Dosage Study: The initial dose evaluated in the trials was low. The study explored whether higher doses correlated with a greater change in primary outcome measures.

Safety and Tolerability Data

Studies have examined the safety profile across various patient cohorts. Safety data was collected based on participant reports.

Common Adverse Events

Reported side effects included nausea, headache, and temporary injection site reactions. These events were the most frequently recorded.

Special Populations Examined

Research has explored the use of the drug in people with mild kidney impairment. Findings were mixed regarding whether differing outcomes were observed in this group. It is not yet clear whether the drug impacts hepatic function markers.


Combination Therapy Research

Studies evaluated the study drug’s potential application for acute flare-ups. The research included quality of life measurements.

  • With Treatment Y: Different outcomes were observed when the study drug was combined with Treatment Y compared to use alone. The combination was evaluated primarily for effects on joint mobility scores.

  • With Placebo: The research compared the outcome measures of the study drug versus a placebo in a blinded setting.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Гвайазулен (FAQ)


Q: Is Гвайазулен considered a natural or synthetic ingredient?

A: Official information indicates that Гвайазулен is a derivative of a sesquiterpene found in chamomile oil. Medical preparations of the compound are typically either highly purified natural derivatives or synthetic equivalents. This approach is taken to ensure the consistency and quality of the active ingredient across approved products.


Q: Is it normal for a product containing Гвайазулен to have a blue color?

A: Yes, the chemical compound Guaiazulene itself is described as having a distinctive dark blue color. This is because the substance is structurally related to other blue compounds found in natural essential oils. The final color of the packaged medicine may vary depending on the specific formulation and other inactive ingredients.


Q: Why is Гвайазулен sometimes combined with other active ingredients in products?

A: The official product profile indicates that Гвайазулен is frequently used in combination products. This approach is often used in formulations alongside agents targeting functional digestive disturbances, aligning with its intended therapeutic profile.


Q: Does exposure to sunlight change the effect of Гвайазулен?

A: Official safety summaries note the potential for increased photosensitivity, which means an abnormal reaction to sunlight, particularly with topical use. Additionally, the active ingredient itself may be sensitive to light exposure, which is why official storage instructions often require protection from light.


Q: Are there reports of Гвайазулен causing sensitivity to light?

A: Yes, safety summaries document the potential for increased photosensitivity, which is an abnormal skin reaction to sunlight. This is noted as a possible adverse reaction, especially when the medicine is used topically.


Q: Why is Гвайазулен sometimes mentioned in relation to stomach issues?

A: The medicine is approved for use via the oral route (taken by mouth), and some formulations are specifically utilized in combination with other agents to address functional digestive disturbances. The oral use is consistent with its classification as an anti-inflammatory and membrane-stabilizing agent.


Q: What Гвайазулен is mainly used for besides the common uses listed?

A: Гвайазулен is officially classified as an anti-inflammatory and anti-allergic agent, which gives it an antiphlogistic (reducing inflammation) role. Its general purpose is defined by its role as an agent utilized to manage discomfort and swelling associated with various inflammatory conditions.


Q: Can Гвайазулен be used by people with sensitive skin?

A: Official documents note that the primary safety restriction is a contraindication for individuals with a known allergy or hypersensitivity to the drug or its components. The regulatory scope does not offer specific guidance concerning use on sensitive skin beyond this primary allergy restriction.


Q: Are there any long-term research studies on the use of Гвайазулен?

A: The research overview of clinical trials reviewed in official documentation mentions tracking primary outcome measures over a period of six months. This duration provides some insight into the drug's profile during use beyond the acute setting.


Q: Can Гвайазулен be used in children, and what are the general age limits?

A: The official regulatory label does not formally impose restrictions on the basis of age. However, official documents note the absence of explicit, dedicated safety data or specific guidelines for pediatric use in the existing content.


Q: Can Гвайазулен interact with common over-the-counter supplements?

A: Official regulatory documentation states there are no formal interaction restrictions cited for use with food, alcohol, or herbal supplements. The official statement relies on the absence of formal interaction restrictions for use with these substances in regulatory documentation.


Q: Why do some people use Гвайазулен for skin redness?

A: People may use Гвайазулен for skin redness because it is classified as an anti-inflammatory agent. Its general purpose is defined as helping to reduce swelling and manage general irritation, which may include the visible sign of inflammation known as redness.


Q: Is there a known maximum duration of use mentioned in official sources for Гвайазулен?

A: Official administration guidelines state that for oral formulations, the course duration is usually limited to 28 days. For topical use, the duration is not set by the label but is determined by a healthcare professional's guidance.


Q: Can Гвайазулен be used on mucous membranes?

A: Yes, official administration guidelines state that Гвайазулен is approved for use via the topical route for localized application on the skin or mucous membranes.


Q: Is Гвайазулен generally well-tolerated by most people?

A: Safety data is collected based on participant reports in studies. The official safety profile is primarily defined by a limited number of adverse reactions, mostly hypersensitivity, which are documented as exceptionally reported events in regulatory sources.


Q: What are the generally expected outcomes when using Гвайазулен as described in research?

A: Research studies investigated primary endpoints such as changes in patient-reported pain scores, the Patient Global Assessment score, and observed changes in swelling. These outcomes are consistent with the intended anti-inflammatory effect of the medicine.


Q: What kind of research has been done on the effect of Гвайазулен on cell health?

A: Research has explored the influence of the drug on T-cell activation markers. Additionally, the mechanism of action includes the stabilization of immune cell membranes, such as mast cells, and its function as an antioxidant that neutralizes free radicals generated during the inflammatory process.


Q: Is the name 'Гвайазулен' protected or is it a common chemical name?

A: Гвайазулен is the official International Nonproprietary Name (INN) for the active ingredient. This is the globally recognized, non-commercial name for the chemical substance, which is defined as 1,4- dimethyl-7-(2- propyl) azulene.


Q: What information do official sources provide about the purity of Гвайазулен?

A: Official descriptions state that medical preparations are typically highly purified derivatives or synthetic equivalents to ensure consistency in the drug product. Chemical standards often require a high minimum purity of the active ingredient, such as ge 99.0% (GC).


Q: Can Гвайазулен be used by people who have a history of inflammatory conditions?

A: The core purpose of the medicine is to provide relief by acting as a membrane stabilizer and anti-inflammatory agent. Its primary benefit is associated with the reduction of discomfort and swelling linked to various inflammatory conditions.


Q: What is the solubility of Гвайазулен in water and oil?

A: Chemical data describes the substance as having low water solubility, meaning it does not mix well with water. However, it is soluble in alcohol and slightly soluble in oil-like substances such as chloroform.


Q: How does the concentration of Гвайазулен in a product relate to its intended purpose?

A: Research has examined the relationship between the concentration of Гвайазулен and its effects. A dosage study mentioned in the research overview explored whether higher doses correlated with a greater change in the primary outcome measures.


Q: How does Гвайазулен compare to Chamomile extract, which also contains Azulene compounds?

A: Гвайазулен is structurally related to the blue compounds found in essential oils like chamomile oil. However, medical products containing Гвайазулен use purified derivatives or synthetic equivalents rather than crude chamomile extract to ensure consistency and a defined amount of the active ingredient.

Advertisements

How should Гвайазулен be stored and disposed of?

How to Store and Dispose of Гвайазулен?

Official regulatory documents specify mandatory conditions for the storage and disposal of medicines containing Гвайазулен to ensure product integrity and safety.

Storage Requirements

The product must be stored at Controlled Room Temperature, typically between 20^circC and 25^circC. The medicine must be kept in a cool, dry place and protected from light to prevent degradation of the active component. For container integrity, the product must be stored in its original packaging with the lid tightly closed. For safety, all medication must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Гвайазулен must not be disposed of in household trash or poured down drains or toilets, as this poses an environmental risk. The product must be disposed of according to local requirements for unused medicine and pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Гвайазулен found in:

A-Z Index: